辛妥珠單抗

辛妥珠單抗
單株抗體
種類	完整抗體
目標	LOXL2（英語：LOXL2）
臨床資料
ATC碼	未分配;
識別資訊
CAS號	1318075-13-6
IUPHAR/BPS	8412;
ChemSpider	none;
UNII	11Z5AIU653;
化學資訊
化學式	C6558H10134N1736O2037S50
摩爾質量	147,492.33 g·mol−1

辛妥珠單抗（INN：simtuzumab；開發代號：GS-6624）是一種人源化單株抗體，設計用於治療纖維化。^[1]它與LOXL2（英語：LOXL2）結合併充當免疫調節劑。^[2]^[3]2016年1月，吉利德科學公司因缺乏療效而終止了針對特發性肺纖維化（IPF）患者的II期臨床研究。^[4]

參考資料

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.
^ Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2) [2024-04-16]. ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237. （原始內容存檔於2024-03-07）.
^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-04-16]. （原始內容存檔 (PDF)於2016-03-04）.
^ Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016 [2024-04-16]. （原始內容存檔於2018-04-18）.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.

[2] Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2) [2024-04-16]. ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237. （原始內容存檔於2024-03-07）.

[3] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-04-16]. （原始內容存檔 (PDF)於2016-03-04）.

[4] Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016 [2024-04-16]. （原始內容存檔於2018-04-18）.

[1]

[2]

[3]

[4]